Gizmo's 13M-User Explosion Fuels $22M Series A in AI Edtech
Rapid scaling in AI edtech: Gizmo grew from 300k users in 2023 to 13M across 120+ countries since 2021 launch.
- $22M Series A led by Shine Capital...

Created by Louis Salazar
AI startup funding updates with deal data, investor commentary, and market impact
Explore the latest content tracked by AI Funding Tracker
Rapid scaling in AI edtech: Gizmo grew from 300k users in 2023 to 13M across 120+ countries since 2021 launch.
Anthropic's restraint on sky-high VC offers highlights maturing AI leader dynamics amid infrastructure boom:
Explosive growth in AI infra funding: Fluidstack seeks $1B at $18B valuation, up sharply from $7.5B talks months ago.
Accel deploys $5B for 20-25 late-stage AI bets at $200M avg, with $4B Leaders Fund V and $650M sidecar.
Lanchi Ventures closed a $560M dual-currency fund for early-stage AI/deep tech in China – notable amid tight funding and a boost for frontier startups, signaling renewed institutional commitment.
VC alert: Accel commits $5B to global AI breakouts, betting on AI's speed from idea to scale in a transforming market.
Investor appetite surges for AI startups beyond hyperscalers, spanning early-to-growth stages in diverse sectors:
Record quarter signals Europe recovery: UK startups raised £5.7bn (+60% YoY), strongest Q1 since 2022.
Key investor insights:
Korea's AI breakthrough: Upstage closes $125.9M Series C first tranche, hitting $1B+ valuation as the nation's first generative AI unicorn. Signals...
Explosive valuation jump for AI data center startup Fluidstack: in talks for $1B round at $18B valuation, months after $7.5B mark on $700M raise.
-...
Early bet on embodied AI hardware/software for real-world tasks:
Chinese AI startup StepFun, maker of popular LLM Kimi, seeks $1B in fresh funding at an $18B valuation while unwinding its offshore structure—a key signal for maturing Chinese AI funding paths.
Helical secures $10M seed to expand its virtual AI platform for drug discovery, as pharma races to cut early-stage risks amid rising R&D costs. Key early bet on AI biotech for investors.